Bioceres S.A. BIOX 深 滬
交易中 10-23 10:11:39 美东时间
2.0612
+0.151
+7.92%
華盛通- 最 高2.09
- 今 開1.91
- 成交量 22.53万股
- 最 低 1.89
- 昨 收 1.91
- 總市值 1.25亿
- 52周最高 7.438
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 1.20
- 委 比 81.82%
- 總股本 6045.28万
- 歷史最高 17.94
- 量 比 1.86
- 振 幅 10.47%
- 歷史最低 1.20
- 每 手 1
- 風險率 1.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit
Biodesix, a diagnostics solutions company, partners with three Colorado-based lung health organizations to host three events in October for healthcare professionals and patients. The events include a lung nodule education seminar by APAPP, a Lung Cancer Centers of Excellence Summit organized by the Go2 Association, and the American Lung Association's "Run the Rocks" fundraiser. These initiatives aim to promote lung health awareness and education,...
10-06 14:13
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value of listed securities (MVLS) requirement under Rule 5550(b)(2). The company previously fell below the $35 million threshold for 30 consecutive business days in March 2025 but received an exception after a hearing in May. Nasdaq confirmed compliance on September 17, 2025, allowing the company to continue listing on the Nasdaq Capital Market.
09-18 11:00
Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Inc. (INBS) has provided an update on its FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System. After submitting its premarket notification in December 2024, the FDA issued an Additional Information (AI) request with over 70 items in February 2025. INBS responded with support from FDA consultants and submitted additional information in August 2025. The FDA has now requested new additional...
09-17 12:30
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Canaccord Genuity Downgrades Bioceres Crop Solutions to Hold, Lowers Price Target to $2.5
Canaccord Genuity analyst Austin Moeller downgrades Bioceres Crop Solutions (NASDAQ:BIOX) from Buy to Hold and lowers the price target from $6.5 to $2.5.
09-10 18:17
Bioceres Crop Solutions Faces Challenging Fiscal Year
Bioceres Crop Solutions ( ($BIOX) ) has released its Q4 earnings. Here is a bre...
09-10 11:53
12 Materials Stocks Moving In Tuesday's Intraday Session
Gainers Bon Natural Life (NASDAQ:BON) stock rose 16.2% to $1.79 during Tuesday...
09-10 01:06
Bioceres Crop Solutions Q4 EPS $(0.76) Misses $0.10 Estimate, Sales $74.70M Miss $110.19M Estimate
Bioceres Crop Solutions (NASDAQ:BIOX) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $0.10 by 859 percent. This is a 2430 percent decrease over losses of $(0.03) per share
09-09 18:08
Bioceres reports Q4 results
Bioceres press release (NASDAQ:BIOX): Q4 net loss was $48.0 million and Adjusted EBITDA1 was negative $4.5 million. For FY25, operating loss was $3.7 million, net loss was $55.2 million and Adjusted E...
09-09 18:08
Earnings Scheduled For September 9, 2025
Companies Reporting Before The Bell • Core & Main (NYSE:CNM) is projected t...
09-09 16:32
